Shenzhen TargetRx, Inc.
13
4
8
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
TGRX-678 Pharmacokinetic Mass Balance
Role: lead
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
Role: lead
TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)
Role: lead
TGRX-326 Pharmacokinetic Food Effect Bioavailability Study
Role: lead
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Role: lead
TGRX-678 Phase I Oral Pharmacokinetic Study
Role: lead
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
Role: lead
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Role: lead
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Role: lead
TGRX-326 Pharmacokinetic Mass Balance
Role: lead
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Role: lead
TGRX-326 Pharmacokinetic Drug Interaction
Role: lead
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Role: lead
All 13 trials loaded